Hemispherx Biopharma, Inc.
Mr. Asensio began his analysis of Hemispherix Biopharma in 1998.  His research quickly revealed the company’s troubling history of litigation.  It seemed Hemispherix used the courtroom to protect itself from criticism and to conceal important information about its business practices from public attention. Of all his short selling projects, Mr. Asensio’s work on Hemispherix was most difficult.  He would have fared better if he simply stayed away from the company altogether.  However, Hemispherix attracted his attention for obvious reasons.  Its stock was grossly overvalued and Mr. Asensio found it unacceptable to permit company executives to exploit uninformed investors.  Mr. Asensio’s coverage of Hemispherix led to his involvement with congressional investigations of the fraudulent company, after efforts to work with regulators failed.  

Hemispherix was one of the last stock frauds committed by the bucket shop Stratton Oakmont before a criminal investigation forced the organization to close.  Mr. Asensio believed the American Stock and Options Exchange (“AMEX”) did not exercise sufficient diligence to protect investors from Hemispherix and so investigated the company himself.  He soon discovered that both a Governor of AMEX and a high ranking floor official owned shares of Hemispherix.  Still worse, Mr. Asensio obtained an offering memorandum in which the AMEX governor boasted of profits earned by trading Hemispherix shares.  

Mr. Asensio’s discoveries soon led him to speak with the press.  In addition, Mr. Asensio met with two members of congress and the Chief of Staff of the Ranking Minority Leader of the House Commerce Committee, responsible for overseeing the U.S. Securities and Exchange Commission (“SEC”).  The Ranking Member wrote the U.S. Comptroller General about the issues with AMEX and noted Mr. Asensio’s allegations.  The Comptroller agreed to investigate the case. Mr. Asensio fully cooperated with this investigation.  In November 2001, the GOA issued its report on the matter (“Improvements needed in the AMEX Listing Program”).  As a result, AMEX was sanctioned and forced to incorporate SEC-mandated regulations into its listing procedures.  The AMEX leadership changed and the new AMEX leader was eventually barred. The Floor Official was also barred.  
Filter     Order     Display # 
Item Title
October 27, 1998 Lyondell grossly overvalued
December 07, 2000 Short Seller raised Intersil concerns prior to today’s pre-announcement.
September 14, 2000 Intersil falls far behind in next generation Wireless LAN products.
December 18, 2001 Hemispherx grossly misrepresents AHRQ report.
February 08, 2001 Hemispherx issues yet another false and fraudulent release.
December 08, 1998 Leading researchers find CFS to be psychosomatic.
October 28, 1998 Hemispherx CFS prevalence disclosures proven false.
October 28, 1998
October 27, 1998 Hemispherx issues blatantly false FDA infraction statement.
October 14, 1998 Hemispherx CFS Phase III and orphan approvals found to be six years old.
October 13, 1998 Ampligen Safety Profile.
October 12, 1998 Hemispherx CFS conference presentations widely ignored.
October 08, 1998 Hemispherx distributes fraudulent Oprah Winfrey videotape.
October 01, 1998 Hemispherx exposed to FDA sanctions.
September 30, 1998
September 30, 1998 Hemispherx attempts to use false CFS prevalence rate
May 03, 2002 Hemispherx continues to attempt to renew its over 13-year-old fraudulent AIDS promotion
November 21, 2001
July 26, 2000 FDA charges Hemispherx with false and misleading Ampligen promote.
March 17, 2000 Hemispherx charged with deception by AIDS organization
September 22, 1998 STRONG SELL RECOMMENDATION
September 22, 1998 Asensio & Company, Inc. releases research report on Hemispherx Biopharma.
September 30, 1998 Hemispherx attempts to prevent stock sale.
October 01, 1998 Dr. Carter’s DuPont and Stratton-Oakmont assertions show intent to defraud.
October 14, 1998 Hemispherx’s hubris expands to legal profession.
October 27, 1998 FDA determines Hemispherx’s Ampligen claims violate regulations.
October 28, 1998 Hemispherx confirms failure to disclose FDA violation.
November 18, 1998 Hemispherx report reveals insider "pump and dump" operation.
March 18, 1999 Hemispherx Suffers Major Loss in Federal Court.
May 13, 1999 AMEX fails to commence enforcement action against Hemispherx.
May 13, 1999 AMEX fails to commence enforcement action against Hemispherx.
May 21, 1999 Hemispherx officers tied to other manipulated stocks.
July 13, 1999 Hemispherx’s Dr. Carter tied to "advocacy group" promotion of Ampligen
July 14, 1999 Hemispherx fabricates false quotes from CFIDS Network.
July 29, 1999 Yet another fraudulent stock promoter tied to Hemispherx.
August 10, 1999 Letter to FDA regarding Hemispherx cost recovery.
August 10, 1999 Hemispherx continues attempts to control its stock trading.
April 19, 2000 Hemispherx’s forced to make damning admissions.
June 01, 2000 KPMG terminates its five-year audit relationship with Hemispherx.
June 08, 2000 Asensio wins against Hemispherx.
July 25, 2000 Hemispherx cited in three criminal indictments.
September 25, 2001 Ampligen and its clinical trials found flawed and useless
October 02, 2001 AMEX’s Hemispherx stock fraud exceeds 30 million shares.
December 18, 2001 HEB uses anti-terrorism scam in latest AMEX pump and dump operation
December 18, 2001 Even Carter’s co-conspirator objects to smallpox claims.
January 28, 2002 NASD's AMEX censured, floor chief barred and Chairman resigns
February 02, 2002 New letter to Congress on significance of Hemispherx's corporate irresponsibility.
February 22, 2002 Hemispherx’s questionable defamation case under jury deliberation.
February 22, 2002 Jury finds Asensio did not defame Hemispherx.
July 14, 2002 "Ill Will" published in the Philadelphia Inquirer.
 
<< Start < Prev 1 2 Next > End >>
Results 1 - 50 of 52
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.